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Previous studies indicate that subjectively reported and objectively 
measured sleep abnormalities at baseline can increase the risk of 
relapse in treated alcoholics. However, previous studies did not in- 
clude both subjective and objective sleep measures in the same 
group of patients. We utilized polysomnography and the Sleep Dis- 
orders Questionnaire to determine if baseline polysomnography in- 
creased the ability to predict relapse beyond the prediction with sub- 
jective measures alone, after controlling for nonsleep variables that 
were associated with relapse. We followed 74 patients with a DSM- 
Ill4 diagnosis of alcohol dependence, of whom 36 relapsed to at 
least some drinking during an average follow-up interval of 5 months. 
Univariate analyses revealed that relapsed patients did not differ 
from abstinent patients at baseline in demographics or psychiatric 
co-morbidity, but they had more prior treatment episodes for alco- 
holism, more difficulty falling asleep, more complaints of abnormal 
sleep, and, on polysomnography, longer sleep latencies, shorter 
rapid eye movement sleep latencies, and less stage 4 sleep percent- 
age than abstinent patients. With a series of logistic regression anal- 
yses, which controlled for age and gender, we demonstrated that 
sleep measures improved the prediction model compared with non- 
sleep variables alone, and that polysomnography-measured sleep 
latency was the most significant predictor variable. We conclude that 
subjective and objective measures of baseline sleep are predictors 
of relapse in treated alcoholic patients. These data also suggest that 
neurophysiological dysfunction contributes strongly to the etiology 
of relapse. Finally, sleep disturbance warrants clinical attention as a 
target of alcoholism treatment. 
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NVESTIGATORS HAVE speculated for >25 years that I sleep disturbances can predispose to relapse among al- 
coholic patients.’-3 Allen and  colleague^,'^^ for example, 
argued that alcoholic patients should have medically super- 
vised hospital care for 7 to 14 days after withdrawal, be- 
cause disturbances in rapid eye movement (REM) sleep 
and memory functioning could lead to relapse during that 
time. However, they did not study drinking outcomes after 
hospitalization to support their recommendation. Gross 
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and Haste3 postulated the existence of a “subacute alcohol 
withdrawal syndrome” characterized by sleep disturbances 
and craving that could persist for months to years and 
increase the risk of relapse. 
Allen and Wagman’ reported that low REM sleep per- 
centage (REM%) was associated with an increased dispo- 
sition to drink in a laboratory setting using a behavioral 
reinforcement paradigm, although experimentally induced 
REM deprivation failed to increase disposition to drinking. 
In a subsequent study, Allen and colleagues6 reported that 
low levels of slow wave sleep (SWS) at baseline predicted 
poor “sobriety” outcome at a 2-month follow-up assess- 
ment after discharge from an alcoholism sleep research 
ward. 
Recently, Gillin and colleagues7 reported that baseline 
sleep abnormalities in male alcoholics predicted relapse to 
drinking within 3 months after discharge from inpatient 
treatment. Specifically, relapsed patients had increased 
“REM pressure” (a composite measure including short- 
ened REM sleep latency, increased REM%, and increased 
REM density) during hospitalization at baseline when com- 
pared with abstainers. There was a nonsignificant trend for 
decreased SWS% in the relapsers, compared with abstain- 
ers. Interestingly, abstainers and relapsers did not differ in 
demographic and clinical measures that are usually prog- 
nostic, such as severity of dependency, depression, and 
social stability. 
Other researchers have suggested that alcoholics may 
relapse to drinking in attempts to self-medicate their in- 
~ o m n i a . ~  Studies indicate that about one-third of alcoholics 
applying to treatment complain of severe insomnia.* We 
are aware of only one study, however, that investigated the 
relationship between subjectively reported sleep distur- 
bance and subsequent drinking in alcoholics. Skoloda et a1.8 
hospitalized patients for 8 weeks, during which time pa- 
tients rated their sleep each morning. After 2 weeks of a 
no-drinking period, patients were allowed to drink speci- 
fied amounts of alcohol while being monitored in the hos- 
pital over the next 4 weeks. Patients who drank during the 
study had reported more sleep disturbance during the first 
2 weeks than patients who abstained during the study. 
We are unaware of any studies that measured both sub- 
jective and objective sleep disturbances as predictors of 
relapse following treatment for alcoholism. It is unknown 
whether polysomnography (PSG) increases the ability to 
predict relapse beyond the prediction with subjective mea- 
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sures alone. In the present study, we examined both sub- 
jective and objective measures of sleep as predictors of 
treatment outcome, after controlling for nonsleep variables 
that can be associated with drinking outcomes in treated 
alcoholics, such as demographics, severity, and co- 
morbidity.' 
We hypothesized that (1) nonsleep variables, such as 
lower education, unmarried status, unemployment, illness 
severity, and psychiatric co-morbidity, would be associated 
with relapse; (2) baseline subjective complaints of poor 
sleep would be associated with relapse; (3) baseline objec- 
tive measures of sleep would be associated with relapse; 
and (4) both subjective and objective sleep measures would 
significantly predict relapse after controlling for nonsleep 
variables that were associated with relapse. 
METHODS 
Su biects 
One hundred and seventy-eight subjects (152 males, 26 females) with 
DSM-111-R diagnoses of alcohol dependence" were recruited from sev- 
eral closely affiliated alcohol treatment programs that broadly divided into 
two treatment systems. The first treatment system recruited 86 subjects 
and consisted of four programs owned and operated by the University of 
Michigan Medical Center and Chelsea Community Hospital, which 
formed a joint venture in 1990 to provide addictions treatment. The four 
programs included an inpatient treatment unit at the University of Mich- 
igan Medical Center, a residential treatment program at Chelsea Com- 
munity Hospital, an older adult inpatient unit at Chelsea Community 
Hospital, and an outpatient program of the joint venture. These programs 
are grouped together because of similarities in subject demographics, as 
well as shared physician and administrative staff. The second treatment 
system recruited 89 patients and consisted of the inpatient alcohol treat- 
ment program at the Ann Arbor Veterans Affairs Hospital (VA system). 
For three subjects, information on treatment site was missing. Subjects 
from the University of Michigan Medical Center and Chelsea Community 
Hospital were more likely than subjects from the VA system to be women 
(29% vs. 5%; x2 = 7.80, df = l , p  = 0.005), to be employed (79% vs. 27%; 
x2 = 16.39, df = l , p  = 0.001), to be married (48% vs. 8%; x2 = 13.91, 
df = 1 , p  = 0.001), to be Caucasian (91% vs. 74%; x2 = 3.51, df = 1, 
p = 0.06), and to be younger (39.3 ? 11.8 vs. 42.4 2 10.0 yr; t = -1.90, 
df = 173, p = 0.06). Thus, our selection of treatment systems ensured a 
demographically heterogeneous sample. 
Each subject was carefully screened for medical and psychiatric conditions 
that might influence sleep measurements. Psychiatric diagnoses were deter- 
mined using a revised version of the Diagnostic Interview Schedule (DIS-III- 
R)," which corresponded to DSM-111-R criteria." Potential subjects were 
excluded if they had a history of significant medical or psychiatric illness, 
including psychosis, current major depression, bipolar disorder, borderline 
personality disorder, heart disease, severe liver disease, seizure disorder (ex- 
cept seizures related to alcohol withdrawal), degenerative or demyelinating 
central nervous system disease, stroke, transient ischemic attacks, or recent 
loss of consciousness due to head trauma. A past history of major depression, 
current dysthymic disorder, or anxiety disorders were not cause for exclusion. 
Likewise, patients with antisocial personality disorder were not excluded 
unless severe (i.e., character traits judged by the investigators to interfere with 
study procedures). Patients were also excluded if they took medications 
known to affect sleep, including antidepressants, anticonvulsants, antihista- 
mines, neuroleptics, sedative-hypnotics, stimulants, centrally acting antihyper- 
tensives (a-methyldopa, reserpine, and clonidine), oral corticosteroids, and 
theophylline. Patients who met DSM-111-R criteria for abuse or dependence 
on substances other than alcohol were not excluded, as long as they were 
substance-free for 2 weeks before their sleep study. Subjects were excluded if 
they worked night shifts or intentionally stayed awake during usual bedtime 
hours. All subjects participated in this study only after signing informed 
consent. The protocol for this study was approved both by the University of 
Michigan Medical Center Institutional Review Board and the Human Sub- 
jects Committee at the VA system. 
Procedures 
Patients were evaluated at two points in time: at baseline and at 
follow-up. The baseline evaluation consisted of a complete medical his- 
tory, physical examination, a psychiatric diagnostic interview, a structured 
interview to determine the substance and psychosocial history, and a sleep 
evaluation. At follow-up, subjects completed a structured interview with a 
research assistant by either telephone or in person, as determined by the 
subjects' preference and feasibility. The follow-up interview was con- 
ducted between 3 and 12 months after the baseline sleep study. Seventy- 
four (42%) of the original 178 subjects completed standardized follow-up 
interviews an average of 5 months after baseline (mean: 142.7 days, SD: 
55.1). Interviews were conducted by trained research assistants of the 
University of Michigan Alcohol Research'Center who were blind to results 
of the subjects' sleep studies. The follow-up interview assessed the sub- 
ject's use of alcohol and other drugs, severity of depressive symptoms, and 
attendance at Alcoholics Anonymous (AA) meetings. 
At baseline, subjects underwent one or more nights of nocturnal PSG 
in the sleep laboratory at the University of Michigan a minimum of 2 
weeks after admission to a treatment center. In some cases, subjects were 
studied from their hospital rooms, which were connected by telemetry to 
the University of Michigan Sleep Laboratory. The mean time period 
between PSG and the patient's last drink was 31.5 (SD: 15.5) days. Only 
data from the first night of sleep monitoring were used for this report, 
because not all subjects completed more than one night of study. 
Sleep was monitored using Sleep Analyzing Computers (OxfordMi- 
crotronics) and standard polysomnographic techniques. Recordings in- 
cluded an electroencephalogram (C3/A2), electrooculogram, submental 
and anterior tibialis electromyogram, electrocardiogram, respiratory effort 
(through abdominal and chest strain gauges), airflow (through nose and 
mouth thermistors), and oxygen saturation (through ear or finger oxime- 
try). Data were digitized using a bedside portable computer and then 
transmitted to Sleep Analyzing Computers in the control room. The 
electroencephalogram channel was digitally filtered to yield a nominal 
band pass of 0.1 to 30 Hz. Data were displayed at a rate of 10 mdsec  as 
a virtual polygraph page on a high-resolution monitor and stored to a hard 
disk at 250 sampleshec. 
Records were masked to remove identifying information so that scorers 
would be blind to diagnostic and treatment status, then manually scored 
using 1-min epochs." Three categories of sleep variables were scored: 
sleep continuity, sleep architecture, and REM sleep indices. Sleep conti- 
nuity included total recording period, total sleep time, sleep efficiency %, 
sleep latency,* and time spent awake after initial sleep onset. Sleep 
architecture included percentage of net sleep time spent in each stage 
(stages 1 to 4 and REM sleep). Delta or SWS was calculated by adding 
stage 3 and stage 4 sleep. REM sleep indices included REM sleep latency, 
corrected REM sleep latency," and REM density. 
Instruments and Measures 
The Sleep Disorders Questionnaire (SDQ) is a 175-item, self- 
administered instrument that was given at baseline to measure subjective 
sleep complaints and q~a1ity.I~ Subjects respond to individual questions 
* Scoring for sleep latency was defined in this study as the time from start 
of recording to onset of stages 2 to 4 or REM sleep with a duration of at least 
10 rnin and with no more than 2 rnin of stage I or 1 rnin of stage 1 +- 1 rnin 
of wakefulness. 
f Corrected REM sleep latency was defined as the time between sleep onset 
and the first REMperiod (at least 3 rnin of REM sleep within 30 min of each 
other) minus intermittent walcefulness during that interval. 
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about the past 6 months (such as “I have trouble getting to sleep at night”) Outcomes 
by choosing among five Likert-scaled response categories: Never (0), 
Rarely (l), Sometimes (2), Usually (3), and Always (4). The SDQ yields 
four clinical-diagnostic scales: (1) sleep apnea, (2) periodic leg movement 
disorder, (3) psychiatric sleep disorder, and (4) narcolepsy. In addition to 
the scaled scores, we selected six individual items a priori for analyses that 
we judged to reflect commonly observed sleep complaints among alcohol- 
ics seen in ordinary clinical practice. The items were, “I often have a poor 
night’s sleep” (item 2), “I have trouble getting to sleep at night” (item 3), 
“My sleep is restless and disturbed” (item 14), “I feel that my sleep is 
abnormal” (item 44), “I feel that I have insomnia” (item 4 9 ,  and “I often 
use alcohol in order to get to sleep” (item 105). For these six items, we 
used a binary scoring system: subjects who answered “never,” “rarely,” or 
“sometimes” were scored as not having the symptom to a clinically signif- 
icant degree, whereas “usually” and “always” responses were scored as 
having the symptom. 
Psychiatric and substance use diagnoses were determined according to 
DSM-111-R criteria” using the revised DIS-111-R.” The DIS-111-R also 
yielded lifetime symptom counts for alcohol dependence (maximum = 9) 
and antisocial personality disorder, which we used as measures of diag- 
nostic severity. Finally, the age of onset of alcohol dependence was 
determined by the DIS-111-R and was defined as the age at which the first 
symptom of the disorder appeared. The Carroll Depression Scale’4 was 
administered to assess self-reported depressive symptoms at baseline and 
at follow-up. Higher scores indicate greater severity of depression. The 
Michigan Alcoholism Screening Test was used as an index of lifetime 
drinking problem severity.I5 The Mini-Mental State Exam was used to 
assess cognitive functioning.I6 The total years of heavy drinking over the 
course of each subjects’ lifetime was assessed using a modified version of 
the Lifetime Drinking History.’’ Heavy drinking was defined as 28 or more 
drinks per week for women and 35 or more drinks per week for men. 
Follow-up measures included drinking status and patterns, other drug 
use, depressive symptoms as determined by readministering the Carroll 
Depression Scale, and attendance at AA meetings. Other drug use was 
defined as any illicit or nonmedical use of amphetamines, cocaine, mari- 
juana, sedative-hypnotics, opiates, hallucinogens, phencyclidine, or inhal- 
ants in the 2 months before interview. Drinking was determined by self- 
report using a timeline follow-back interview.18 The timeline follow-back 
method uses a timeline calendar protocol to examine daily alcohol con- 
sumption over the follow-up interval using monthly calendars. The reli- 
ability and validity of this method have been demonstrated in several 
RESULTS 
Effects of Follow-up Status 
We conducted univariate analyses comparing subjects 
whom we followed (n = 74) to subjects lost to follow-up 
(n = 104). Before tests of significance, continuous variables 
were assessed for normality. Nonnormal variables were 
transformed to approximate normal distributions before 
conducting further analyses. Continuous variables were an- 
alyzed with t tests. Dichotomous variables were tested with 
either the x2 test or the Fisher’s exact test if cell sizes were 
too small. All tests were two-tailed. 
Significant differences were found between subjects who 
were followed and subjects who were lost to follow-up for 
only two of 42 variables (Table 1). Subjects who were 
followed had engaged in heavy drinking over a longer 
period of time and had less stage 2 sleep on baseline PSG 
than subjects who were not followed. Importantly, neither 
variable was associated with relapse in the followed group. 
The 74 subjects who completed follow-up interviews 
were categorized into two groups (abstained vs. relapsed) 
based on their drinking status during the follow-up interval. 
A relapse was defined as any drinking of alcohol during the 
follow-up interval. Conversely, abstinence was defined as 
the absence of drinking any alcohol (ie., continuous absti- 
nence) during the follow-up interval. Outcome differences 
between the abstained and relapsed groups were assessed 
using t tests, Fisher’s exact tests, and x2 tests for univariate 
analyses. 
Slightly more than one-half or 38 of the 74 subjects who 
completed the follow-up evaluation abstained from alco- 
hol, whereas the other 36 subjects relapsed. Subjects who 
relapsed drank an average (mean) of 27% of days and a 
mean of 2.7 (SD: 4.9) drinkddrinking day during the 
follow-up interval. During the follow-up interval, subjects 
who had relapsed attended fewer AA meetings, were less 
likely to have used other drugs, and had higher depression 
scores than subjects who had abstained (Table 2). However, 
differences in drug use and depression scores were not 
significant after correcting for the number of tests (Bon- 
ferroni correction). 
Predictors of Relapse 
We first conducted univariate analyses comparing those 
who relapsed (n = 36) to those who abstained (n = 38), 
both for descriptive purposes and to select variables for the 
regression analyses. Univariate analyses revealed nominally 
significant differences (p < 0.05) between abstainers and 
relapsers for treatment site, number of prior alcohol treat- 
ment episodes, and several sleep variables (Table 3). Treat- 
ment at the VA treatment system was associated with 
relapse. Subjects who relapsed also had more prior treat- 
ment episodes than subjects who abstained did. No other 
demographic, substance-related, or psychiatric differences 
were found at baseline. Furthermore, there was no statis- 
tically significant difference between the abstainers (139 ? 
53 d) and the relapsers (146 2 57 d) in length of the 
follow-up interval, so the two outcome groups did not differ 
in their time risk for relapse. Finally, none of the differ- 
ences in nonsleep variables were significant after correcting 
for the number of tests (Table 3). 
Subjects who relapsed reported more subjective sleep 
disturbance at baseline than subjects who subsequently 
abstained, including complaints of difficulty falling asleep 
and abnormal sleep (Table 3). Relapsed subjects also had 
higher SDQ psychiatric scale scores than abstinent subjects, 
although no differences between the two outcome groups 
were found for other SDQ scale scores (narcolepsy, sleep 
apnea, and periodic leg movement disorder). The SDQ 
scale score results indicate that the increased sleep com- 
plaints of the relapsed patients at baseline were more likely 
to be associated with psychiatric distress than with sleep 
disorders, such as narcolepsy, sleep apnea, and periodic leg 
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Table 1. Differences Between Followed and Not Followed Groups 
Not followed group Followed group 
Baseline variables (n = 104)’ (n = 74)’ 
Demographics and Treatment Site 
Age 40.2 t 10.7 41.6 2 11.6 
Race (% white) 85 82 
Education (years) 12.8 t 2.0 13.2t  1.5 
Married (%) 33 29 
Employed (%) 57 53 
Lives alone (%) 22 23 
Treatment site (% from VA system) 48 53 
Gender (% male) 87 84 
Severity of alcohol dependence 
Age of Onset 20.3 2 8.2 20.0 ? 6.7 
Years of heavy drinking? 10.7 t 8.1 13.8 t 10.0 
MAST Score 40.5 t 11.2 42.8 ? 9.5 
DSM-Ill-R symptom count 7 . 6 t  1.6 7.6 2 1.5 
Prior alcohol treatments (no.) 1.8 t 1.1 2.2 2 2.3 
Family history-positive (1 st degree) 62 % 60% 
Carroll Depression Score 6.9 t 5.4 9.0 ? 7.8 
DSM-Ill-R Antisocial Symptom Count 6.2 2 3.7 6.2 t 4.2 
MMSE Score 28.3 t 2.3 28.2 t 3.0 
Used drugs in past 12 months (%) 28 30 
Tobacco use (pack-years) 20.3 t 19.4 26.0 t 19.5 
Psychiatric scale 36.2 t 22.6 40.4 2 25.5 
Frequent poor sleep (item 2) 26.3% 25.7% 
Difficulty falling asleep (item 3) 26.3% 35.1 % 
Restless and disturbed sleep (item 14) 19.2% 17.6% 
Abnormal sleep (item 44) 18.2% 17.6% 
Insomnia (item 45) 6.1 % 6.8% 
Alcohol used to sleep (item 105) 39.8% 50.0% 
Total recording period (min) 384.8 t 37.4 384.8 t 30.6 
Total sleep time (min) 301.4 2 51.2 
Sleep efficiency (%) 81.1 2 11.6 78.4 2 11.9 
Sleep latency (min)$ 35.4 2 35.5 39.3 t 32.8 
Wake time after sleep onset @in)$ 38.1 2 34.7 
Stage 1 (%) 22.3 t 11.8 25.2 2 14.6 
Stage 2 (%)t 49.1 ? 11.0 45.1 t 13.1 
Stage 3 (YO)$ 4.6 2 4.9 4.7 t 5.1 
Stage 4 (%)$ 3.6 t 5.8 4.3 2 7.1 
REM sleep (%) 20.5 2 6.8 20.6 t 6.9 
REM sleep latency (min) 75.5 t 53.4 64.0 2 47.2 
REM sleep latency corrected (min) 60.1 t 43.8 
REM density 1.2 t 0.6 1.3 t 0.6 
Psychiatric and drug co-morbidity 
Antisocial personality disorder 29% 21 % 
Lifetime drug use disorder (%) 45 49 
SDQ 
PSG 
31 1.6 t 52.8 
27.6 ? 24.7 
sws (%) 8.2 ? 8.6 9.0 2 10.0 
70.5 t 50.0 
Means t SD are presented. Some variables have smaller sample sizes because of missing data. VA = Veterans Affairs: MAST = Michigan Alcoholism Screening 
t p < 0.05. 
$ Statistical test was performed on transformed values not shown in the table. 
Test: MMSE = Mini-Mental State Exam; SDQ = Sleep Disorders Questionnaire; PSG = Polysomnography. 
movement disorder. Polysomnographic measures that dis- 
tinguished the two subject groups were prolonged sleep 
latency, decreased stage 4%, and shortened REM latency 
in the subjects who relapsed (Table 3). There was a non- 
significant trend (p < 0.1) for the relapse group to have 
lower sleep efficiency than the abstinent group. Overall, 
subjects who subsequently relapsed had greater distur- 
bances of both objective and subjective sleep at baseline 
than subjects who abstained, although only sleep latency 
was significant after adjusting for the number of tests. 
Logistic regression analyses were performed to deter- 
mine whether baseline sleep measures were useful for pre- 
dicting relapse after controlling for other clinical variables. 
Three domains of predictor variables were considered. The 
first domain was comprised of nonsleep clinical variables, 
including demographics, severity of alcohol dependence, 
psychiatric co-morbidity, and other drug use. The second 
domain contained subjective sleep measures from the SDQ, 
and the third domain consisted of Objective sleep measures 
from baseline PSG. 
Two series of logistic regression analyses were per- 
formed. The preliminary series were used to select vari- 
ables for the final series. In the preliminary series, we ran 
separate backward-elimination logistic regression analyses 
for each variable domain, entering all variables in the do- 
main that significantly differed (p < 0.05) between out- 
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Table 2. Outcome Differences Between Subjects Who Abstained and 
Relapsed 
Abstained group Relapsed group 
Outcome variables (n = 38)’ (n = 36)’ 
% days abstinentt 100 t 0.0 73.4 t 30.1 
Average drinkddrinking dayt 0 2.7 t 4.9 
Maximum drinkddrinking day7 0 15.4 t 13.0 
Carroll Depression Score at follow-up* 10.9 2 10.5 
Maximum AA meetingdweek (no.)* 4.5 t 2.8 2.9 2 2.7 
AA meetings in past 30 days (no.)t 5.7 t 6.3 
Used other drugs (%)* 25 5 
6.0 2 7.5 
10.7 t 7.8 
Means t SD are presented. Some variables have smaller sample sizes 
t p < 0.005. Significant after applying Bonferroni correction (p  < 0.007). * p < 0.05. Not significant after applying Bonferroni correction ( p  < 0.007). 
because of missing data. AA = Alcoholics Anonymous. 
come groups in the univariate analyses. To control for age, 
gender, and the length of the follow-up interval, these 
variables were also included in the preliminary regression 
analyses. However, we did not include treatment site in the 
regression analyses, because we were interested in patient 
characteristics, not treatment characteristics that predicted 
outcome. Moreover, none of the patient characteristics that 
were associated with relapse (number of prior treatments, 
sleep latency, stage 4%, REM sleep latency, and subjective 
sleep variables) differed between patients recruited from 
the two treatment systems (data not shown). REM sleep 
latency and corrected REM sleep latency were highly cor- 
related (Pearson r = 0.98, p = 0.0001); thus, only the 
corrected REM sleep latency was entered because of its 
higher statistical significance in the univariate analyses 
( p  = 0.017 for corrected REM sleep latency vs. p = 0.022 
for REM sleep latency). Finally, to make the odds ratio for 
corrected REM sleep latency more interpretable, we di- 
vided each patient’s value for this variable by 10 so we 
could calculate the odds of relapse for each 10-min increase 
in corrected REM sleep latency. 
The variables selected by domain from the preliminary 
regression analyses were: number of prior alcohol treat- 
ments (nonsleep domain); SDQ question 3, “I have trouble 
getting to sleep at night” (subjective sleep domain); and 
sleep latency and corrected REM sleep latency (objective 
sleep domain). A double dagger in Table 3 represents the 
selected variables. 
For the final series of logistic regression analyses, we 
examined four models. The models differed in the number 
and order of domains entered (Table 4). To examine the 
effect of adding polysomnography to information gathered 
in routine clinical interviews, we first entered the nonsleep 
domain (model l), then the subjective sleep domain (model 
2a), and finally the objective sleep domain (model 3). This 
order of entry was chosen to determine if sleep measures 
added predictive ability after controlling for other clinical 
variables known to be associated with treatment outcome. 
Of the sleep measures, subjective sleep variables were en- 
tered before objective sleep variables to determine if PSG 
added predictive ability to information ordinarily gathered 
as part of routine clinical interviews. Once a variable was 
entered into the analysis, it was forced to stay in the model. 
Table 3. Baseline Differences as a Function of Outcome Group 
Abstained group Relapsed group 
Baseline predictor variables (n = 38)’ (n = 36)’ 
Demographics and treatment site 
Age 
Gender (YO male) 




Lives alone (%) 
Treatment site (YO from VA system)t 
Age of onset 
Years of heavy drinking 
MAST Score 
DSM-Ill-R symptom count 
Prior alcohol treatments* (no.)§ 
Family history-positive (1 st degree) 
Psychiatric and drug co-morbidity 
Carroll Depression Score 
Antisocial symptom count 
Antisocial personality disorder 
MMSE Score 
Lifetime drug use disorder (%) 
Used drugs in past 12 months (%) 
Tobacco use (pack-years) 
Psychiatric Scale§ 
Frequent poor sleep (item 2) 
Difficulty falling asleep* (item 3)t 
Restless and disturbed sleep (item 14) 
Abnormal sleep (item 44)5 
Insomnia (item 45) 
Alcohol used to sleep (item 105) 
Total recording period (min) 
Total sleep time (min) 
Sleep efficiency (%) 
Sleep latency$ (min)t,# 
Wake time after sleep onset (min)# 
Stage 1 (%) 
Stage 2 (%) 
Stage 3 (%)# 
Stage 4 (Om)§. # 
sws (%) 
REM sleep (%) 
REM sleep latency @in)§ 
REM sleep latency corrected$ (min)§ 
REM densitv 
Severity of alcohol dependence 
SDQ 
PSG 
40.7 t 11.8 
76 
82 





20.2 2 8.2 
13.2 t 10.2 
43.0 2 9.4 
7.4 t 1.4 
1.6 t 0.8 
66% 
7.6 2 7.6 
5.6 t 4.2 
15% 
27.8 2 3.6 
60 
39 
22.1 t 23.0 







383.0 t 30.8 
309.0 t 51.4 
80.8 t 12.1 
29.1 2 25.0 
38.5 2 35.9 
23.8 t 13.2 
46.4 t 12.6 
4.5 t 4.6 
5.6 t 8.0 
10.1 2 10.3 
19.7 f 7.4 
76.0 t 53.0 
71.8 2 49.8 
1.3 t 0.6 
42.5 t 11.5 
92 
83 





19.8 t 4.9 
14.3 t 10.0 
42.5 2 9.6 
7.7 t 1.5 
2.9 t 3.0 
54% 
10.5 t 7.8 
6.8 2 4.2 
29% 
28.5 t 2.2 
37 
20 
30.0 f 14.2 






61 .I % 
386.6 t 30.6 
293.4 2 50.4 
75.8 2 11.3 
50.0 t 36.7 
37.7 t 34.0 
26.7 t 15.9 
43.8 f 13.7 
4.9 t 5.7 
2.9 2 5.9 
7.8 t 9.8 
21.7 t 6.1 
51.3 2 36.9 
47.8 ? 32.8 
1.2 f 0.5 
Note: After correcting for the number of tests in each domain (nonsleep, 
subjective sleep, and objective sleep domains), only sleep latency remained 
statistically significant ( p  = 0.0024). 
* Means 2 SD are presented. Some variables have smaller sample sizes 
because of missing data. VA = Veterans Affairs; MAST = Michigan Alcoholism 
Screening Test: MMSE = Mini-Mental State Exam. 
t p < 0.01. 
$ Variables selected for final series of logistic regression models. 
5 p < 0.05. 
# Statistical test was performed on transformed values not shown in the table. 
After each variable domain was entered, we determined the 
overall significance of the model, the percentage of cases 
correctly classified, the amount of variance accounted for, 
and the odds ratios for each variable (Table 4). 
In model 1, the nonsleep variable (number of prior treat- 
ments) correctly predicted drinking status at follow-up for 
64% of the sample and accounted for 15% of the variance 
as measured by the Nagelkerke21 R2. The x2 for the model 
was 8.6 (df = 1, p = 0.0034). Adding the subjective sleep 
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Table 4. Final Logistic Regression Models 
Model Model Model Model 
Statistical measure It 2at 2b6 3# 
~~~ 
Odds ratios for predictor variables 
Prior treatment episodes 1.56' 1.42 1.46 1.35 
Trouble falling asleep (SDQ item 3) - 3.12' - 2.88 
Corrected REM sleep latency - - 0.89 0.88 
Sleep latency - - 2.42" 2.35* 
% of cases correctly predicted 64 72 68 72 
Model ,y2 p value 0.0034 0.0014 0.0001 0.0001 
p values are as follows: 
* significance level of x' statistic for this variable is p < 0.05; ** significance 
t Only nonsleep domain entered. * Subjective sleep domain added to model 1 to model the effect of interview- 
5 Objective sleep domain added to model 1 to model the etiology of relapse. 
#All  three domains are forced into the model. 
level of x2 statistic for this variable is p < 0.01. 
gathered variables. 
variable (SDQ item 3) to model 1 resulted in model 2a, 
which predicted drinking status for 72% of the sample and 
accounted for 22% of the variance. The model x 2  increased 
to 13.1 (df = 2,p = 0.0014). When all three domains were 
forced into the regression, model 3 predicted drinking sta- 
tus for 72% of the sample and accounted for 37% of the 
variance. The model x 2  increased to 23.7 (df = 4, p = 
To examine processes involved in the etiology of relapse, 
we first entered the most distal variable, which was the 
number of prior treatment episodes (model 1 again). Pa- 
tients who presented for their current treatment episode 
with a history of past treatment failures were assumed to 
have increased illness severity that resulted in treatment 
resistance. Although illness severity and treatment resis- 
tance may have a neurophysiological basis, our only neu- 
rophysiological measure, PSG, was a measure of current 
dysfunction that did not necessarily precede the previous 
treatment episodes. However, we cannot rule out on the 
basis of this study that the neurophysiological dysfunction 
that we measured via PSG did not precede the previous 
treatment failures. Nevertheless, we entered the objective 
sleep domain second (model 2b), because we reasoned that 
as a current neurophysiological measure, it was more prox- 
imal to study outcome than past history. We entered the 
subjective sleep domain last (model 3 again) because we 
interpreted subjective sleep as an indirect measure of ob- 
jective sleep that is influenced by psychological factors. A 
modest but significant correlation between trouble falling 
asleep (SDQ item 3) and sleep latency (r = 0.25, p = 0.03) 
supported our assumption that the subjective and objective 
sleep variables, respectively, were measuring a similar pro- 
cess. Thus, we viewed objective sleep as the neurophysio- 
logical basis of subjective sleep; consequently, objective 
sleep was conceptualized as a more primary, etiological 
predictor of relapse than subjective sleep. When the objec- 
tive sleep variables were added to model 1, model 2b 
resulted, which predicted drinking status for 68% of the 
sample and accounted for 32% of the variance. The model 
x2 was 20.5 (df = 3, p = 0.0001). 
0.0001). 
The odds ratios for variables in each step of the model 
are shown in Table 4. The odds ratios changed very little 
after adding each subsequent domain. The final model 
(model 3) shows that each additional episode of prior 
treatment increased the odds of relapse by 1.4-fold. Having 
difficulty falling asleep increased the odds of relapse by 
2.9-fold. Also, the odds of relapse decreased by a factor of 
0.9 for every 10-min increase in corrected REM sleep 
latency. Finally, the sleep latency variable was transformed 
using a natural logarithm; thus, each 1% increase in sleep 
latency yielded a 2.4% increase in the odds of relapse. 
DISCUSSION 
We found support for our hypothesis that nonsleep vari- 
ables would be associated with relapse, although demo- 
graphics and co-morbidity were not. Only the number of 
prior alcohol treatments, which we interpreted as a mea- 
sure of treatment resistance and illness severity, was signif- 
icantly associated with relapse in our sample. Likewise, we 
found that both subjective and objective sleep measures 
predicted relapse after treatment for alcoholism even after 
controlling for prior alcohol treatments. In short, patients 
who relapsed had worse sleep at baseline than patients who 
abstained during a 5-month follow-up period. 
Our results are consistent with those of Gillin et al.7 in 
showing an effect of shortened REM sleep latency on 
alcoholic relapse, although we did not find an effect for 
REM% or REM density. In Gillin's study, increased REM 
density predicted relapse in just 1 of 2 samples tested. 
Likewise, we reported preliminary findings in which in- 
creased REM% and decreased SWS% were predictors of 
relapse,22923 but those sample sizes were smaller than in this 
study and previously we did not control for all the clinical 
variables that we analyzed in this study. The work of Allen 
et a1.,6 although also suggestive of a predictive effect of 
decreased SWS on relapse, involved a small sample size, 
poorly defined outcome measures, and a lack of control for 
confounding clinical variables, such as age and severity of 
dependence. We tentatively, conclude, therefore, that 
SWS, REM%, and REM density are inconsistent and un- 
stable predictors of relapse, in contrast to shortened REM 
sleep latency that was a consistent predictor across two 
recent studies. 
Both objective and subjective measures of difficulty fall- 
ing asleep at night were associated with relapse to drinking. 
Subjectively reported trouble falling asleep predicted 
drinking outcomes in at least one other study.' However, 
PSG was not performed in that study, so subjects may have 
been responding to sleep questionnaires with generalized 
dissatisfaction about their lives or specific misperceptions 
about their sleep. The present study is the first to demon- 
strate that both objectively measured and subjectively re- 
ported sleep disturbances can predict relapse in the same 
group of alcoholic patients. Moreover, objective sleep dis- 
turbance predicted relapse, even after controlling for sub- 
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jective sleep measures and other clinical variables. In partic- 
ular, PSG-measured sleep latency was the most significant 
predictor variable. 
Patients are often told by clinicians that sleep distur- 
bances are common during early recovery and will improve 
with abstinence. The assumption is that if treatment fo- 
cuses on the goal of abstinence, then sleep will improve 
naturally without further intervention. Unfortunately, this 
assumption may only be partially correct. For example, 
some patients manifest persistent sleep abnormalities de- 
spite prolonged a b ~ t i n e n c e . ~ ~ - * ~  Moreover, accumulating 
evidence now suggests that alcoholic patients with the most 
disturbed sleep are most likely to relapse. Therefore, we 
recommend that sleep disturbances be monitored closely 
with careful consideration of both beha~ioral~’-~~ and phar- 
macological treatments. It is tempting to speculate that 
antidepressants, most of which are known to prolong REM 
sleep latency,30 may be useful in preventing relapse in 
alcoholic patients with sleep disturbances. It is also possible 
that sedating antidepressants, such as trazodone and mir- 
tazapine, might prevent relapse by shortening sleep latency 
in selected patients. Benzodiazepines and other cross- 
dependent sedative-hypnotics are probably best avoided in 
alcoholics (except for short-term detoxification) due to 
their toxicity when combined with alcohol and their poten- 
tial for abuse by alcoholic patients.31932 
Several methodological concerns must be considered 
when interpreting these results. First, relapse status, the 
treatment outcome variable of interest, was determined 
solely by self-report without biochemical or other corrob- 
oration, such as by a friend or family member. Second, 
relapse status was the only outcome variable investigated, 
and our definition of relapse was very stringent, not allow- 
ing for any drinking during the follow-up period. The fact 
that sleep disturbance can predict a return to drinking may 
be less clinically valuable than predicting a “full” relapse 
with hazardous drinking and adverse consequences. Future 
studies should use multidimensional outcome measures. 
Third, only one night of sleep was recorded, which did not 
allow subjects to adjust to the “first night effect” of sleeping 
under novel conditions. Fourth, patients were followed 
over differing time periods. However, the length of the 
follow-up period did not differ between the two outcome 
groups, and it did not predict relapse in the preliminary 
regression analyses. Fifth, patients did not receive uniform 
treatments. Indeed, we found that treatment site was sig- 
nificantly associated with outcome. Nevertheless, other 
variables that predicted outcome did not differ between 
treatment sites. Moreover, the use of diverse treatment 
sites ensured a heterogeneous sample and may increase the 
generalizability of the results. 
Sixth, only 42% of patients receiving baseline sleep as- 
sessments were followed over time and were included in 
our analyses of relapse predictors. The low follow-up rate 
reflects the fact that longitudinal outcomes were added as 
a secondary area of interest after starting our primary 
investigations on the effects of alcoholism and aging on 
sleep abn~rmalit ies.~~ Although the representativeness of 
the followed sample may be questioned, followed and not 
followed patients did not differ on any baseline variables 
that predicted outcome. Nevertheless, they did differ on 
the percentage of stage 2 sleep and the duration of heavy 
drinking. Moreover, one reasonably assumes that a “lost- 
to-follow-up” group has a greater proportion of relapsed 
patients than a followed group. On the other hand, we have 
no theoretical reason or empirical evidence from the exist- 
ing literature to hypothesize that the percentage of stage 2 
sleep is related to alcoholic relapse. Regarding duration of 
heavy drinking, we interpreted this variable as a measure of 
illness severity, and we hypothesized that increased illness 
severity would be related to relapse. Yet, we paradoxically 
found fewer years of heavy drinking in the not followed 
group. Thus, the available data suggest that the potential 
compromise to study integrity because of this problem is 
low. Nevertheless, our results must be interpreted with 
caution until replicated by other studies with better 
follow-up rates, more consistent follow-up intervals, better 
characterization of treatment variables, and multidimen- 
sional outcome measures that are corroborated. 
Strengths of this study include a relatively large sample 
size for a polysomnographic investigation of alcoholic pa- 
tients, co-measurement of both subjectively reported and 
objectively measured sleep in the same group of patients, 
and a heterogeneous sample that included women, patients 
with commercial insurance, and patients treated in a VA 
Medical Center. 
In summary, both subjective and objective measures of 
baseline sleep were associated with relapse in treated alco- 
holic patients. The ability of PSG to predict outcome status 
after controlling for other variables reflects the etiological 
importance of neurophysiological factors in the relapse 
process. Finally, sleep disturbances warrant clinical atten- 
tion as a target of treatment and should be considered in 
alcoholism treatment trials. 
ADDENDUM 
Since the submission of this article, two other articles 
were recently published that provide further evidence that 
sleep abnormalities are predictors of alcoholic 
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